Making the scientists fulfil their promises

Article Abstract:

The value of shares in the biotechnology sector fell by one third during 1997 after 12 companies announced that clinical trials had not been successful. The market is now worth a little over 3 billion pounds sterling. British Biotech (BB) dominates the market and its progress tends to shape how investors view the market. BB's shares have fallen by 50% since 1996 and are now worth only 820 million pounds. Share prices fell when BB announced that trail results of an anti-cancer drug would not be available until 1999. Problems with two other drug trails also weakened investors' confidence.

Securities

---

Mapping the genome busters. (biotechnology company shares_

Article Abstract:

Biotechnology companies have seen poor performance of shares for several reasons, including the failure of clinical trials, delays in products coming to market and proposed products that did not materialise. The share prices of biotech companies can fluctuate excessively making them hard to value. Investors wanting to determine probable winners and inevitable losers should determine whether a company's cash reserves are sufficient to finance product development. They should also determine whether the company owns the rights to its technology.

Market share

---

Mergers could save wilting sector

Article Abstract:

Choroscience and British Biotech are thought to be considering a merger in a move which could trigger consolidation in the United Kingdom biotechnology industry. There is speculation that Peptide Pharmaceuticals and Medeva are involved in bid negotiations. Biotechnology companies have not performed well in 1998. Both Chiroscience and British Biotech are involved in cancer research, and a merger between the two would create a strong drug discovery and development company.

Mergers, acquisitions and divestments, Chiroscience Group PLC

Similar abstracts:

• Abstracts: The current status of outcomes assessment in marketing education. An evaluation of journals used in doctoral marketing programs
• Abstracts: Estate planning advantages of LLCs over S corporations. S corporation reform. Top ten reasons for professionals to consider using LLCs
• Abstracts: The case against index-linked gilts. The real problem with gilts. Political worries hold back gilts
• Abstracts: Pick of the bunch. Lincat puts on a disappointing display. Mucking about
• Abstracts: Facelift for Ferruzzi. Ship with no rudder. Power struggle

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.